Chief Executive Officer
Blueprint Medicines
Kate Haviland
Kate Haviland is an inspirational and impactful leader to the "Blue Crew" at Blueprint Medicine, one who champions patient care, manages with empathy, and helps employees thrive. She has played a central role in the design and advancement of one of the deepest precision therapy pipelines in the sector, while creating a highly engaged employee culture that sets both her and Blueprint apart.
At Blueprint, Kate has served in highly strategic roles for more than half of the company's existence, first as Chief Business Officer, then Chief Operating Officer, and now Chief Executive Officer and a member of the company's board of directors. Over this time, she served as the founding chair of the portfolio management team, formed and executed business development strategy, drove global capital investment plans, and played a key role in capital market financings that have raised more than $2.5 billion to finance the business during her tenure.
Under Kate's stewardship, Blueprint Medicines experienced transformative growth into a commercial-stage biotech company, with two globally commercialized precision therapies and multiple collaborations that have enabled the company to accelerate the delivery of those therapies to more patients around the world.
In May of 2023, she oversaw the U.S. Food and Drug Administration (FDA) approval of AYVAKIT® (avapritinib) for the treatment of indolent systemic mastocytosis, following its approval in advanced systemic mastocytosis in 2021. AYVAKIT is the first and only medicine approved by the FDA to treat indolent systemic mastocytosis, as well as the only treatment approved across the spectrum of indolent and advanced systemic mastocytosis. At the end of the third quarter 2023, Kate and her team announced that AYVAKIT achieved 90% net product revenue growth year-over-year and more than 35% growth in treated patients quarter-over-quarter.
Kate works diligently to ensure that Blueprint tackles important societal issues like equity, diversity and inclusion. Under her leadership, Blueprint achieved more than 50% female representation companywide, and an executive team comprised of 50% women. This is above the biotech industry standard—Fierce Biotech reported only 34% of executives were women in 2022. Kate has been included on Fierce Pharma's Fiercest Women in Life Sciences list, as well as by PharmaVoice as part of its PharmaVoice 100.
Prior to joining Blueprint, Kate held leadership roles with Idera Pharmaceuticals, Sarepta Therapeutics, PTC Therapeutics and Genzyme. Kate currently serves on the board of directors of Bicara Therapeutics and as chair of the board of directors at Fulcrum Therapeutics and is a member of the audit and nomination and corporate governance committees.
Under Kate's stewardship, Blueprint Medicines experienced transformative growth into a commercial-stage biotech company, with two globally commercialized precision therapies and multiple collaborations that have enabled the company to accelerate the delivery of those therapies to more patients around the world.
In May of 2023, she oversaw the U.S. Food and Drug Administration (FDA) approval of AYVAKIT® (avapritinib) for the treatment of indolent systemic mastocytosis, following its approval in advanced systemic mastocytosis in 2021. AYVAKIT is the first and only medicine approved by the FDA to treat indolent systemic mastocytosis, as well as the only treatment approved across the spectrum of indolent and advanced systemic mastocytosis. At the end of the third quarter 2023, Kate and her team announced that AYVAKIT achieved 90% net product revenue growth year-over-year and more than 35% growth in treated patients quarter-over-quarter.
Kate works diligently to ensure that Blueprint tackles important societal issues like equity, diversity and inclusion. Under her leadership, Blueprint achieved more than 50% female representation companywide, and an executive team comprised of 50% women. This is above the biotech industry standard—Fierce Biotech reported only 34% of executives were women in 2022. Kate has been included on Fierce Pharma's Fiercest Women in Life Sciences list, as well as by PharmaVoice as part of its PharmaVoice 100.
Prior to joining Blueprint, Kate held leadership roles with Idera Pharmaceuticals, Sarepta Therapeutics, PTC Therapeutics and Genzyme. Kate currently serves on the board of directors of Bicara Therapeutics and as chair of the board of directors at Fulcrum Therapeutics and is a member of the audit and nomination and corporate governance committees.
